Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
Hongle Yan, Chunyi Huang, Xuejun Shen, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 23

Showing 23 citing articles:

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 47
Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
Ana G. Petrovic, Dunja Igrec, Karla Rožac, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 6, pp. 4544-4556
Open Access | Times Cited: 22
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Minjeong Park, Hayeon Kim, Myeong Gyu Kim, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 693-704
Open Access | Times Cited: 19
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
Peipei Zhou, Ying Tan, Zhenning Hao, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 14
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Maria Zachou, Pagona Flevari, Narjes Nasiri‐Ansari, et al.
European Journal of Clinical Pharmacology (2023) Vol. 80, Iss. 1, pp. 127-150
Open Access | Times Cited: 14
Mapping the landscape of research on insulin resistance: a visualization analysis of randomized clinical trials
Sa’ed H. Zyoud
Journal of Health Population and Nutrition (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 5
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Cardiology Research (2023) Vol. 14, Iss. 1, pp. 12-21
Open Access | Times Cited: 11
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study
J. Yeh, Philip N. Newsome
Hepatology (2024) Vol. 79, Iss. 6, pp. 1255-1257
Open Access | Times Cited: 3
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022)
Open Access | Times Cited: 14
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco, Olga Disoteo, Vincenzo De Geronimo, et al.
Endocrines (2024) Vol. 5, Iss. 1, pp. 72-86
Open Access | Times Cited: 2
Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
Xiaojing Huang, Huiling Chen, Song Wen, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 1809-1819
Open Access | Times Cited: 6
Polyphenol-Rich Extract of Fermented Chili Pepper Alleviates Insulin Resistance in HepG2 Cells via Regulating INSR, PTP1B, PPAR-γ, and AMPK Pathways
Tao Wang, Meiqi Li, Shengbao Cai, et al.
Fermentation (2023) Vol. 9, Iss. 2, pp. 84-84
Open Access | Times Cited: 5
Exploring the hypoglycemic mechanism of chlorogenic acids from Pyrrosia petiolosa (Christ) Ching on type 2 diabetes mellitus based on network pharmacology and transcriptomics strategy
Hanjiao He, Qing Wei, Jiao Chang, et al.
Journal of Ethnopharmacology (2023) Vol. 322, pp. 117580-117580
Closed Access | Times Cited: 5
Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial
YongSheng Cao, Shujie Cao, Jiangang Zhao, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Differential association of abdominal, liver, and epicardial adiposity with anthropometry, diabetes, and cardiac remodeling in Asians
Vivian Lee, Yiying Han, Desiree‐Faye Toh, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Comparison of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter protein-2 inhibitors on treating metabolic dysfunction-associated steatotic liver disease or metabolic dysfunction-associated steatohepatitis: systematic review and network meta-analysis of randomised controlled trials
Ruhan Xu, Bo Liu, Xianghai Zhou
Endocrine Practice (2024)
Closed Access | Times Cited: 1
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Nuojin Guo, Hekai Shi, Hao Zhang, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 11, pp. 1465-1474
Closed Access | Times Cited: 2
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 2
Differential Association of Abdominal, Liver and Epicardial Adiposity with Anthropometry and Cardiac Remodeling in Asians
Calvin Chin, Vivian Lee, Yiying Han, et al.
Research Square (Research Square) (2024)
Open Access
Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Basile Njei, Yazan A. Al‐Ajlouni, Samira Yaya Lemos, et al.
Authorea (Authorea) (2024)
Open Access
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Basile Njei, Yazan A. Al‐Ajlouni, Samira Yaya Lemos, et al.
Cureus (2024)
Open Access
Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
Maria Sudoł, Katarzyna Dąbek, Michał Ochwat, et al.
Quality in Sport (2024) Vol. 35, pp. 56304-56304
Open Access
Page 1

Scroll to top